Today, the FDA refused to approve the new drug application for Qnexa (Vivus Pharmaceuticals: VVUS), a combination weight loss drug that has been touted as one of the best new weight loss drugs in 10 years. The vote by the panel was 6 in favor, and 10 opposed.

What is interesting is that the panel had no issue with the effectiveness of this drug. In fact, the data presented was extremely compelling as to not only weight loss, but reduction of blood pressure, lipids and blood sugar levels. It also resulted in significant improvements in sleep apnea.